Key Insights

Highlights

Treatment Research

2 treatments under study, led by Pegylated Liposomal Doxorubicin Pld Doxil

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00785798Phase 1/2Terminated

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

Showing all 1 trials

Research Network

Common Treatments

  • Pegylated Liposomal Doxorubicin Pld Doxil1
  • Vorinostat1

Active Sponsors

  • Yale University1
  • Merck Sharp & Dohme LLC1

Top Investigators

Related Conditions

  • Relapsed Lymphomas1

Activity Timeline